Malignant Pleural Mesothelioma Treatment

Authored by Chinmay Jani, published on 2026-09-01 18:38:20.0

The algorithm broadly reflects contemporary malignant pleural mesothelioma management by separating histology and incorporating immunotherapy (nivolumab/ipilimumab) for non-epithelioid disease and multimodality therapy including surgery and/or radiation in selected epithelioid, potentially resectable cases. It is directionally aligned with major guidelines and pivotal trials, but it is underspecified on staging, operability criteria, performance status, and preferred systemic regimens (including pemetrexed/platinum ± bevacizumab and chemo-immunotherapy options). The role and timing of radiation in multimodality approaches remains nuanced and center-dependent, and non-epithelioid resection is generally uncommon outside highly selected cases.